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Joint effect of obesity and TNFA variability on asthma: two
international cohort studies
Abstract
Obesity is a risk factor for asthma. Adipose tissue expresses pro-inflammatory molecules including
tumour necrosis factor (TNF), and levels of TNF are also related to polymorphisms in the TNF-a
(TNFA) gene. The current authors examined the joint effect of obesity and TNFA variability on asthma
in adults by combining two population-based studies. The European Community Respiratory Health
Survey and the Swiss Cohort Study on Air Pollution and Lung and Heart Disease in Adults used
comparable protocols, questionnaires and measures of lung function and atopy. DNA samples from
9,167 participants were genotyped for TNFA -308 and lymphotoxin-a (LTA) +252 gene variants.
Obesity and TNFA were associated with asthma when mutually adjusting for their independent effects
(odds ratio (OR) for obesity 2.4, 95% confidence interval (CI) 1.7-3.2; OR for TNFA -308
polymorphism 1.3, 95% CI 1.1-1.6). The association of obesity with asthma was stronger for subjects
carrying the G/A and A/A TNFA -308 genotypes compared with the more common G/G genotype,
particularly among nonatopics (OR for G/A and A/A genotypes 6.1, 95% CI 2.5-14.4; OR for G/G
genotype 1.7, 95% CI 0.8-3.3). The present findings provide, for the first time, evidence for a complex
pattern of interaction between obesity, a pro-inflammatory genetic factor and asthma.
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ABSTRACT: Obesity is a risk factor for asthma. Adipose tissue expresses pro-inflammatory
molecules including tumour necrosis factor (TNF), and levels of TNF are also related to
polymorphisms in the TNF-a (TNFA) gene. The current authors examined the joint effect of obesity
and TNFA variability on asthma in adults by combining two population-based studies.
The European Community Respiratory Health Survey and the Swiss Cohort Study on Air
Pollution and Lung and Heart Disease in Adults used comparable protocols, questionnaires and
measures of lung function and atopy. DNA samples from 9,167 participants were genotyped for
TNFA -308 and lymphotoxin-a (LTA) +252 gene variants.
Obesity and TNFA were associated with asthma when mutually adjusting for their independent
effects (odds ratio (OR) for obesity 2.4, 95% confidence interval (CI) 1.7–3.2; OR for TNFA -308
polymorphism 1.3, 95% CI 1.1–1.6). The association of obesity with asthma was stronger for
subjects carrying the G/A and A/A TNFA -308 genotypes compared with the more common G/G
genotype, particularly among nonatopics (OR for G/A and A/A genotypes 6.1, 95% CI 2.5–14.4; OR
for G/G genotype 1.7, 95% CI 0.8–3.3).
The present findings provide, for the first time, evidence for a complex pattern of interaction
between obesity, a pro-inflammatory genetic factor and asthma.
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T
here is increasing evidence suggesting that
obesity is a risk factor for asthma in
children and adults [1–3]. Obesity has
been associated with both incident and prevalent
asthma as well as with severity of the disease.
Results from cohort studies have not, however,
been consistent. Experimental studies support
this association but the mechanisms linking
obesity with asthma are complex and remain
uncertain [2, 4–7]. Obesity affects pulmonary
physiology and induces changes in immunity or
inflammatory status. Adipose tissue expresses a
number of pro-inflammatory molecules, includ-
ing tumour necrosis factor (TNF), in a pattern
that could be analogous to the immune function
of T-lymphocytes and macrophages [8].
Twin studies suggest that obesity and asthma may
be caused by shared genetic (genetic pleiotropy)
risk factors [9]. Some genes associated with obesity
are located on asthma consensus loci on chromo-
somic regions 5q, 6p, 11q and 12q [6], and TNF-a
(TNFA) is among the few genes that have been
associated with both asthma and obesity [4, 5].
TNF is a potent pro-inflammatory cytokine,
mainly secreted by macrophages. TNF is involved
in the regulation of a wide spectrum of biological
processes, including cell proliferation, differentia-
tion, apoptosis, lipid metabolism and coagulation,
and has been implicated in a variety of diseases,
including autoimmune diseases, insulin resis-
tance, cancer and inflammation of asthmatic air-
ways. TNFA and lymphotoxin-a (LTA; also named
TNFb) genes are members of the TNF super-
family. TNFA and LTA are located within the class
III region of the major histocompatibility complex
region on chromosome 6p21.3, in a cluster of
13 kb, which also includes lymphotoxin-b, a
region previously linked to asthma in different
genome scans. Polymorphisms in TNFA and LTA
may affect levels of TNF in the airways. The TNFA
-308 G/A polymorphism, located in the promoter
region of TNFA, has been associated with
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increased promoter activity and secretion of TNF [10]. The LTA
+252 A/G polymorphism, located in the first intron of the LTA
gene, seems to be associated with a high LTA expression [11]. A
recent meta-analysis that included the population reported in
the current study has shown that the TNFA -308 A and LTA +252
G alleles are both positively associated with asthma [12].
In the current study, the evaluation of a joint effect of obesity
and genetic variants in the TNFA and LTA genes on asthma is
presented, by examining different proposed pathways asso-
ciating these biological factors with respect to this disease.
MATERIAL AND METHODS
Study population
The analyses in the current report are based on two studies. The
European Community Respiratory Health Survey (ECRHS) is a
population-based cohort study conducted in 10 countries [13,
14]. The population-based Swiss Cohort Study on Air Pollution
and Lung and Heart Disease in Adults (SAPALDIA) was
conducted in eight Swiss communities [15, 16]. Initially, 5,065
participants from ECRHS and 6,071 participants from
SAPALDIA with complete interview data and DNA samples
for genotyping were included [12]. Some subjects from Basel,
Switzerland (n5400), were initially included in both datasets,
but remained only in the SAPALDIA cohort during the
analyses. Due to differences between the two studies in age at
inclusion, the present analysis was restricted to the 9,167
subjects who were aged ,50 yrs at inclusion. Subjects in both
studies could be considered as being mainly of European-
Caucasian origin. Ethical approval was obtained for each centre
from the appropriate institutional ethics committee and written
consent was obtained from each participant.
Asthma and atopy assessment and obesity evaluation
ECRHS and SAPALDIA used identical questionnaires for
assessment of respiratory symptoms and asthma. Asthma
status at baseline was evaluated in the early 1990s (ECRHS-I
and SAPALDIA-I), while the effects of changes in obesity and
asthma were assessed at follow-up for both cohorts. The
median length of follow-up was 8.9 yrs. The asthma defini-
tions used in the present analysis were similar to those used in
previous publications [12, 17]. All subjects defined as having
asthma had responded positively to an initial question ‘‘Have
you ever had asthma?’’ The main asthma definition of ‘‘current
asthma’’ was based on further positive responses to either of
two questions: ‘‘Have you had an attack of asthma in the last
12 months?’’ or ‘‘Are you currently taking any medicines
including inhalers, aerosols or tablets for asthma?’’ ‘‘Physician-
diagnosed asthma’’ was defined as a further positive response
to the question ‘‘Was this confirmed by a doctor?’’
Height and weight were assessed in both studies (table 1).
Body mass index (BMI) was calculated as weight divided by
squared height in metres. BMI was divided into four
categories: underweight (BMI ,20 kg?m-2), normal weight
(BMI 20 to ,25 kg?m-2), overweight (BMI o25 to ,30 kg?m-2)
and obese (BMI o30 kg?m-2).
Skin prick tests were performed in ECRHS and SAPALDIA
(Phazet1; Pharmacia and Upjohn Diagnostics AB, Uppsala,
Sweden). At baseline in both studies, atopic subjects were
defined as having positive tests to at least one common
aero-allergen (Dermatophagoides pteronyssinus, timothy grass,
cat and Cladosporium herbarum).
Candidate single nucleotide polymorphism selection and
genotyping
On the basis of previous studies and functional data [10–12],
two single nucleotide polymorphisms (SNPs) were selected for
genetic analysis in the two cohorts, TNFA -308 (rs1800629) and
LTA +252 (rs909253). In SAPALDIA, these polymorphisms
were genotyped by real-time PCR. In ECRHS, SNPs were
genotyped using the SNPlexTM platform (Applied Biosystems,
Foster City, CA, USA). Genotyping was performed at the
Centre for Genomic Regulation in the Barcelona Node of the
Centro Nacional de Genotipado in Spain. The agreement in
genotyping in subjects from Basel, Switzerland (n5400), who
were included in both ECRHS and SAPALDIA and were
genotyped by both methods, was 99.8%. Genotype distribution
for both alleles was consistent with Hardy–Weinberg equili-
brium (HWE) in the control group (p.0.05). A previous analysis
of these cohorts [12] found similar effects of TNFA -308 and
LTA +252 on asthma, possibly due to strong linkage disequili-
brium between the loci (Chi-squared57516.29, disequilibrium
TABLE 1 Characteristics of the population in the European
Community Respiratory Health Survey (ECRHS)
and the Swiss Cohort Study on Air Pollution and
Lung and Heart Disease in Adults (SAPALDIA)
studies
Controls Cases of current asthma
ECRHS SAPALDIA p-
value
ECRHS SAPALDIA p-
value
Subjects n 4224 4364 426 132
Age yrs 34.2¡7.2 36.3¡8.8 ,0.01 33.7¡7.1 36.5¡8.9 ,0.01
Sex
Male 2036 (48.2) 2197 (50.5) 0.03 172 (40.4) 60 (45.8) 0.32
Female 2188 (51.8) 2149 (49.4) 254 (59.6) 71 (54.1)
Smoking status
Never 1796 (42.5) 2021 (46.3) ,0.01 219 (51.7) 65 (49.2) 0.16
Ex 892 (21.1) 947 (21.7) 93 (21.9) 39 (29.5)
Current 1534 (36.3) 1392 (31.9) 112 (26.4) 28 (21.2)
BMI kg?m-2
Mean¡SD 24.1¡3.8 23.8¡3.6 ,0.01 24.7¡4.6 24.5¡4.5 0.62
,20 387 (9.9) 688 (15.8) ,0.01 33 (8.3) 16 (12.2) 0.31
20 to ,25 2194 (56.2) 2495 (56.7) 218 (54.9) 77 (58.8)
25 to ,30 1072 (27.5) 990 (22.8) 96 (24.2) 25 (19.1)
o30 249 (6.4) 203 (4.7) 50 (12.6) 13 (9.9)
TNFA -308
G/G 2809 (72.1) 3246 (74.4) 0.04 248 (62.4) 99 (75.0) 0.02
G/A 980 (25.1) 1011 (23.2) 132 (33.2) 31 (23.5)
A/A 110 (2.3) 103 (2.4) 17 (4.3) 2 (1.5)
LTA +252
A/A 1997 (47.5) 2089 (47.9) 0.52 165 (38.8) 67 (51.6) ,0.01
A/G 1750 (41.6) 1832 (42.0) 202 (47.5) 59 (44.7)
G/G 455 (10.8) 439 (10.1) 58 (13.6) 6 (4.5)
Data are presented as median¡SD or n (%), unless otherwise stated. BMI: body
mass index; TNFA: tumour necrosis factor-a; LTA: lymphotoxin-a.
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constant (D9)50.98, p,0.001). Results were also similar for the
present analysis evaluating obesity, and results for LTA +252
are, therefore, not shown.
Statistical analysis
The statistical analyses were performed using logistic regres-
sion and SNPassoc (version 1.5–1) R package (version 2.6.1)
[18, 19]. Logistic regression models were used, adjusted for
country (ECRHS) or study area (SAPALDIA), sex, age and
smoking status. SNPs were tested in control samples for
deviations from HWE [20]. Genotype distribution for both
alleles was consistent with HWE in the control group
(p .0.05). D9 and Chi-squared p-values for marker indepen-
dence were estimated to determine linkage disequilibrium
between both genetic markers. Population stratification in
ECRHS data was assessed using two different methods. First,
the analysis of 26 unlinked markers (supplementary table E1)
was performed by the genomic control approach [21] used in
the earlier analysis [12]. It was found that population
stratification had a minimal effect (inflation factor 1.06).
Secondly, analysis using EIGENSTRAT software (version
1.01) [22] using the same 26 markers showed no evidence of
population stratification (supplementary fig. E1).
RESULTS
The general characteristics of the study population are
summarised in table 1. Among controls, significant but slight
differences were observed between cohorts for mean age, sex,
smoking status and mean BMI. Compared with controls, cases
with current asthma were more often females and younger,
and reported less smoking.
The multivariate analysis of obesity, TNFA -308 polymorphism
and current asthma (table 2) indicated that both obesity and
the TNFA -308 polymorphism are associated with asthma. The
risk estimates for TNFA -308 and obesity were very similar in
the unadjusted models compared with the model adjusting
mutually for both risk factors, indicating that the effect of
each factor is not dependent on the other. Adjustment by
smoking status or further adjustment by atopy did not modify
the risk estimates. Similar associations were observed for
physician-diagnosed asthma, while no clear pattern was
observed between BMI categories and atopy.
The percentages of underweight and obese subjects were
higher for carriers of the A/A TNFA -308 genotype (18% and
2%, respectively) compared with the more frequent G/G
genotype (13% and 1%, respectively). These differences were
only statistically significant for underweight subjects (p50.02).
The association of TNFA -308 with underweight was only
observed in the ECRHS and not in SAPALDIA but the
difference between studies was not statistically significant.
Figure 1 shows risk estimates for obesity and current asthma
after stratifying by TNFA -308 genotypes. The analysis was
performed combining G/A and A/A carriers (dominant genetic
model) because analysis for each genotype was not possible
due to the low prevalence of A/A (3%). The risk tended to be
higher for those with the G/A and A/A genotypes (odds ratio
(OR) 3.17, 95% confidence interval (CI) 1.73–5.66) compared
with the G/G genotype (OR 1.94, 95% CI 1.28–2.85), but the
interaction was not statistically significant (p50.40). This
difference in risk was more pronounced among nonatopics
for current asthma (OR 6.09, 95% CI 2.49–14.39) and physician-
diagnosed asthma (OR 5.62, 95% CI 2.79–11.02), while the
TNFA -308 polymorphisms did not seem to modify the effect of
obesity and asthma in atopics (OR 1.67, 95% CI 0.77–3.28, and
OR 1.66, 95% CI 0.84–3.15, respectively). The interaction
between TNFA and obesity in relation to asthma among
nonatopics was statistically significant (p50.05 for current
asthma and p50.03 for physician-diagnosed asthma).
The association of TNFA -308 with asthma stratified by BMI is
shown in table 3 (contrary to figure 1, which showed the ORs
for BMI stratified by TNFA -308). A positive association of
TNFA -308 polymorphisms with current asthma was observed
for all subjects (OR 1.34, 95% CI 1.10–1.62). The highest risks
were observed for those underweight (OR 1.94, 95% CI 1.00–
3.68) and obese subjects (BMI o30 kg?m-2; OR 1.70, 95% CI
0.89–3.19). The increased risk for TNFA -308 among obese
TABLE 2 Multivariate model associating current asthma
with tumour necrosis factor-a (TNFA) -308
polymorphism and obesity
Variables OR (95% CI) Mutually adjusted OR (95% CI)
BMI kg?m-2
,20 0.78 (0.56–1.07) 0.76 (0.54–1.06)
20 to ,25 1 (ref) 1 (ref)
25 to ,30 0.95 (0.75–1.20) 0.91 (0.71–1.15)
o30 2.36 (1.72–3.21) 2.23 (1.60–3.06)
TNFA -308
GG 1 (ref) 1 (ref)
GA 1.33 (1.08–1.62) 1.41 (1.14–1.73)
AA 1.41 (0.83–2.28) 1.48 (0.85–2.42)
Logistic regression adjusted by country, age, sex, smoking status. OR: odds
ratio; CI: confidence interval; BMI: body mass index; ref: reference value.
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FIGURE 1. Odds ratios (bars) and 95% confidence intervals (lines) for the
association of obesity (body mass index (BMI) o30 kg?m-2) and current asthma by
atopy and tumour necrosis factor-a (TNFA) -308 genotypes. h: all subjects; &: G/
G; &: G/A+A/A. The reference group corresponded to subjects with normal weight
(BMI 20 to ,25 kg?m-2). The logistic regression was adjusted for country, age, sex
and smoking status.
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subjects were observed in both SAPALDIA (OR 2.42) and
ECRHS (OR 1.56), while there was heterogeneity between
studies in the results for underweight (test for heterogeneity
Q55.00, p50.03). Among underweight subjects, the increased
risk of current asthma was associated with TNFA -308
irrespective of atopic status (table 3), while the increased risk
of TNFA -308 among obese subjects was only observed for
nonatopics, with an OR of 3.15 (95% CI 1.18–8.54) for current
asthma and 1.93 (95% CI 0.85–4.26) for physician-diagnosed
asthma. The interaction term for TNFA -308 and obesity was
the same as that shown for figure 1.
DISCUSSION
In the present study, the joint effects of obesity and the TNFA
gene were evaluated in adults with asthma. The findings
suggest that obesity and TNFA are associated with asthma in a
complex pattern that involves both independent and combined
pathways, and that some of these pathways may be modified
by sex and atopic status. The combination of two studies
increased statistical power but also served to verify the
consistency of findings in two populations examined with
similar protocols but by different research groups.
The mechanisms through which obesity provokes asthma
remain unclear. Common genetic pathways have been pro-
posed as an explanation for the covariation of obesity and
asthma [5]. The current study is the first to evaluate both
obesity and TNFA variants simultaneously in a large popula-
tion sample. A model showing the possible links between
obesity, TNF and asthma is proposed in figure 2.
There is rising evidence that links both obesity and TNFA
variants to asthma (pathways A and B, fig. 2). Results of
several cross-sectional and prospective studies [1, 2, 4, 8], as
well as a recent meta-analysis [1], are in favour of obesity being
a risk factor for asthma (pathway A, fig. 2). Results from the
ECRHS and SAPALDIA studies, particularly the effect of
weight gain during the follow-up period on the occurrence of
new-onset asthma, support these findings [23]. Obesity may
affect the pulmonary physiology and modify the immunolo-
gical system, leading to pro-inflammatory processes [4–6, 8].
Some studies have suggested an increased risk for asthma and
asthma-related symptoms among underweight subjects [24–27].
The reasons for the impact of underweight on asthma are
unclear [24], and further research is needed to elucidate
potential pathways. Although this effect was not observed in
the current study, an increased risk of TNFA -308 was seen
among underweight subjects, which may suggest a role of
underweight and systemic inflammatory state on asthma.
The TNFA -308 polymorphism has been linked with an
increased TNF expression [10] and has been previously
associated with asthma [12]. The current results indicate that
TNFA -308 is associated with asthma (pathway B, fig. 2) but
not with atopy [12].
Only a weak association was found between TNFA -308 and
obesity (pathway C, fig. 2), and an association was also found
with underweight, although this was observed only in the
ECRHS and not in SAPALDIA study. Results from a meta-
analysis suggest that TNFA -308 is associated with the
TABLE 3 Association of tumour necrosis factor-a (TNFA) -308 G/A+A/A genotype and asthma stratified by body mass index (BMI)
categories
All Atopic asthma Nonatopic asthma
OR (95% CI)# p-value" OR (95% CI)# p-value" OR (95% CI)# p-value"
Current asthma 1.34 (1.10–1.62) 1.35 (1.05–1.72) 1.33 (0.93–1.87)
BMI ,20 1.94 (1.00–3.68) 0.24 2.32 (1.02–5.24) 0.23 2.29 (0.68–7.43) 0.21
BMI 20 to ,25 1.27 (0.97–1.64) ref 1.25 (0.90–1.73) ref 1.05 (0.63–1.70) ref
BMI 25 to ,30 1.52 (0.99–2.30) 0.53 1.64 (0.95–2.78) 0.43 1.17 (0.54–2.38) 0.83
BMI o30 1.70 (0.89–3.19) 0.41 1.05 (0.41–2.55) 0.66 3.15 (1.18–8.54) 0.05
Physician-diagnosed asthma 1.10 (0.93–1.29) 1.18 (0.96–1.46) 0.94 (0.70–1.24)
BMI ,20 1.43 (0.85–2.36) 0.30 1.61 (0.84–3.06) 0.45 1.58 (0.66–3.56) 0.10
BMI 20 to ,25 1.04 (0.83–1.09) ref 1.09 (0.83–1.43) ref 0.70 (0.45–1.06) ref
BMI 25 to ,30 1.13 (0.78–1.62) 0.80 1.32 (0.80–2.12) 0.58 0.93 (0.52–1.59) 0.46
BMI o30 1.76 (0.99–3.10) 0.10 1.32 (0.57–2.99) 0.78 1.93 (0.85–4.26) 0.03
OR: odds ratio; CI: confidence interval; ref: reference value. #: logistic regression adjusted by country, sex, age and smoking status. ": for interaction between TNF -308
G/A+A/A and BMI categories; reference categories BMI 20 to ,25 kg?m-2 and G/G genotype.
Atopy, sex
B
TNFA/TNF
Obesity
Asthma
A
DC
FIGURE 2. Pathways associating obesity, the tumour necrosis factor-a (TNFA)
gene/tumour necrosis factor (TNF) cytokine and asthma. –––:independent effects
of obesity (line A) and TNFA/TNF (line B) on asthma, for which there exists strong
evidence. ?????: pathways for which epidemiological evidence is less clear; the
potential interaction of obesity and TNFA (lines C and D) and the potential
modification of these effects by atopy and sex.
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development of obesity [28]. In contrast, experimental studies
suggest that TNF is involved in body weight homeostasis by
increasing lipolysis, favouring muscle cell catabolism and
stimulating general proteolysis [29].
In a reverse pathway, TNF could be involved in inflammatory
changes produced by obesity (pathway D, fig. 2). This pathway
could only be examined indirectly by evaluating whether the
effect of obesity on asthma was modulated by the TNFA -308
polymorphism. As hypothesised, the asthma risk associated with
obesity was strongest in carriers of the TNF -308 A allele. This
observation is consistent with the hypothesis that the influence of
adipose tissue on TNF signalling is genotype dependent. Adipose
tissue expresses several cytokines, including TNF-a [8], that may
simulate the immune function of T-lymphocytes and macro-
phages [4]. Increased levels of TNF in serum have been observed
in obese subjects [30, 31], as well as in asthmatics [32]. TNF-
mediated inflammation is common in both obesity and asthma
and it is plausible that it is upregulated in both conditions [5].
It has been suggested that the effect of obesity on asthma and
atopy could be sex dependent, being greater in post-pubertal
and adult females than in males [1, 4, 6, 8, 23]. The current
results suggest a slightly stronger effect of obesity on
physician-diagnosed asthma among females compared with
males. The present study also reported an increased risk for
atopy in females and a significant interaction between sex and
obesity for atopy. However, overall results are inconsistent [1,
4, 7, 8, 14], including those in a recent meta-analysis [33].
The current study found that the effect of obesity was stronger
for subjects with nonatopic asthma. Other studies have also
reported similar findings [34, 35], or have found an association
for asthma but not for other atopic diseases [36, 37]. GILLILAND
et al. [34] and KRONANDER et al. [35] found an increased risk for
nonatopic asthma regardless of sex, while they observed an
increased risk for atopic asthma only among obese females.
Raised levels of high-sensitivity C-reactive protein, an inflam-
matory marker known to be related to smoking, obesity and
cardiovascular disease, were found to be significantly asso-
ciated with respiratory symptoms and nonallergic asthma but
not with allergic asthma [38].
The current analysis presents, for the first time a joint evaluation
of obesity and TNF in a large population-based study. Despite the
large sample size, the evaluation of asthma and obesity in relation
to the minor TNFA -308 genotype (A/A) was based on small
numbers. In addition, some of the pathways evaluated related to
obesity could have different effects in pre- and post-menopausal
females. In current study, most females were pre-menopausal.
Other issues that could not be adequately addressed in the
present study regard other measures of obesity, such as waist-to-
hip ratio, that have been shown to be associated with a high risk
of cardiovascular diseases [39]. Finally, the analysis of the impact
of obesity on TNF-a signalling would have been more informa-
tive had circulating TNF-a levels been measured.
The present study strengthens the existing evidence for an effect of
obesity and tumour necrosis factor on asthma, and shows for the
first time that obesity interacts with genetic factors in the causation
of asthma. In conclusion, the study shows that obesity and tumour
necrosis factor are associated with asthma in a complex pattern
that involves both independent and combined effects.
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